GreggWStone Profile Banner
Gregg W. Stone MD Profile
Gregg W. Stone MD

@GreggWStone

Followers
30K
Following
8K
Media
506
Statuses
5K

Interventional cardiologist, trialist, innovator, educator, husband, father, loyal friend

New York and the world
Joined December 2016
Don't wanna be here? Send us removal request.
@GreggWStone
Gregg W. Stone MD
6 days
For all of you who stop after the presentation: nothing is more true than the lesson in this image. So many abstracts are never published, and of those that are, the interpretation almost always changes, sometimes radically.
5
15
52
@GreggWStone
Gregg W. Stone MD
16 days
To improve primary PCI outcomes in STEMI: routinely anticoagulate with bivalirudin and cangrelor; use intravascular imaging guidance; SSO2 for anterior MI; Impella for neuro-preserved cardiogenic shock. Doing all (evidence-based) would markedly improve survival.
16
29
171
@GreggWStone
Gregg W. Stone MD
21 days
RT @dranulala: Proud to be here- .to serve, to care, to innovate, to learn, to teach, & to grow. 🫀🩺.@DLBHATTMD #ValentinFuster #SaminSharma….
0
2
0
@GreggWStone
Gregg W. Stone MD
23 days
Free article link:
@GreggWStone
Gregg W. Stone MD
23 days
Our new editorial in JSCAI discussing the propensity matched SCAAR data showing reduced 10-year rates of MI after Absorb BVS c/w metallic DES. We conclude "The enduring promise of “leaving nothing behind” continues to warrant our persistent investigation and optimism."
Tweet media one
0
5
23
@GreggWStone
Gregg W. Stone MD
23 days
Our new editorial in JSCAI discussing the propensity matched SCAAR data showing reduced 10-year rates of MI after Absorb BVS c/w metallic DES. We conclude "The enduring promise of “leaving nothing behind” continues to warrant our persistent investigation and optimism."
Tweet media one
1
6
34
@GreggWStone
Gregg W. Stone MD
1 month
As far as I know, this is the world’s longest-running annual vulnerable plaque and patient meeting. It is extremely high-level. Definitely worth registering and watching virtually.
@MillbrookMed
Millbrook Medical Conferences
1 month
Registration Now Open: VPM 2025.🗓️ 15–17 September 2025 🌐 Virtual Attendance Only. #VPM2025 is a forum where ideas that have shaped the field of ischaemic heart disease have been born. With a world-leading faculty of nearly 80 international pioneers from top institutions, VPM
Tweet media one
0
9
31
@GreggWStone
Gregg W. Stone MD
1 month
RT @MillbrookMed: Registration Now Open: VPM 2025.🗓️ 15–17 September 2025 🌐 Virtual Attendance Only. #VPM2025 is a forum where ideas that h….
0
6
0
@GreggWStone
Gregg W. Stone MD
1 month
So surprised the answers are all over the place. Holdover effect of the JAMA article >10 yrs ago showing assn of ICU RHC use & death, since debunked, w/many studies showing assn w/RHC use & lower death in shock. But no definitive RCTs. I would use RHC in ~100% of shock cases.
@GreggWStone
Gregg W. Stone MD
2 months
How often do you insert a right heart catheter to manage cardiogenic shock?.
4
10
59
@GreggWStone
Gregg W. Stone MD
2 months
How often do you insert a right heart catheter to manage cardiogenic shock?.
6
13
30
@GreggWStone
Gregg W. Stone MD
2 months
Our new PROSPECT II study in Circulation comparing untreated non-obstructive lsns in STEMI & NSTEMI. ~4 such lsns per pt. 2-feature high-risk plaques were equally present (in 38.8% vs. 32.7%; P=0.11). 4-yr rates of untreated lesion-related MACE were also similar (8.6% vs 7.8%).
Tweet media one
3
23
106
@GreggWStone
Gregg W. Stone MD
2 months
I'm thrilled to announce that we've completed randomizing 1252 pts with LVEF <40% and complex CAD to high-risk PCI with Impella CP support vs. control. Now we are in the 1-year follow-up phase and then the results of the PROTECT IV trial will be reported.
9
40
302
@GreggWStone
Gregg W. Stone MD
2 months
Which term do you prefer?.
5
6
9
@GreggWStone
Gregg W. Stone MD
2 months
Saddened beyond words. Dimitri was a very special person.
@KambisMashayek1
Kambis Mashayekhi
2 months
We are deeply saddened by the passing of our esteemed colleague and dear friend, Dr. Dimitri Karmpaliotis. Dimitri was not only a world-class interventionalist, but also a visionary thinker, a generous mentor, and a tireless advocate for better patient care. @CtoEuro.
0
3
21
@GreggWStone
Gregg W. Stone MD
3 months
Our publication in EHJ: In ILUMIEN IV, >50% of lesions were mod/sev calcified. OCT-guided PCI in calcified lesions reduced 2-yr rate of TVF and serious MACE - one of the best uses for OCT guidance! Free access link:
Tweet media one
Tweet media two
Tweet media three
2
37
115
@GreggWStone
Gregg W. Stone MD
3 months
2nd new PROSPECT II publ, this in JACC Int: hs-CRP (inflammation) was independently associated with both diffuse cor plaque and lipid deposition as well as focal vulnerable plaques. Coupled with the JACC article: LDL & CRP → diffuse plaque and lipid whereas Lp[a] & CRP → VP.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
1
14
53
@GreggWStone
Gregg W. Stone MD
3 months
Our JACC publ from PROSPECT II. ↑ TC, LDL-C, & non-HDL-C were strongly associated with pancoronary athero and lipid deposition. ↑ Lp(a) was strongly associated with focal vulnerable plaques→unique role for Lp(a) role in plaque progression & vulnerability -synergistic with LDL.
Tweet media one
Tweet media two
Tweet media three
Tweet media four
2
25
89
@GreggWStone
Gregg W. Stone MD
3 months
@Elsayed_balba3
Elsayed Balbaa
3 months
@GreggWStone Could you please share it's link.
0
1
5
@GreggWStone
Gregg W. Stone MD
3 months
Our publ of outcomes of PCI vs. CABG in ISCHEMIA now online in AHJ. Even though this was NOT a randomized comparison, everyone wanted to see it. For the 1203 pts (385 CABG, 818 PCI), the adj 4y primary event rate was 14.5% for CABG & 13.2% for PCI (diff 1.3%, 95%CI -4.9% - 7.7%).
4
22
81
@GreggWStone
Gregg W. Stone MD
3 months
Celebrating my son-in-law’s PhD graduation from Yale - everything on the cake is meaningful. Future of the next generation is bright!
Tweet media one
14
4
122
@GreggWStone
Gregg W. Stone MD
3 months
Our publ in EHJ: state of the art review of intrer-atrial shunting - potentially a major breakthrough in HFrEF and selected pts with HFpEF. Add to this the ongoing placebo-procedure controlled ALLAY-HFrEF trial which has just started randomizing 350 HFrEF pts.
Tweet media one
Tweet media two
Tweet media three
0
8
48